BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 11:47:00 AM | Browse: 1460 | Download: 1504
 |
Received |
|
2013-09-04 16:39 |
|
Peer-Review Started |
|
2013-09-05 08:54 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2013-10-14 18:11 |
|
Revised |
|
2013-11-02 18:37 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-01-06 20:11 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-01-06 20:24 |
|
Articles in Press |
|
|
|
Edit the Manuscript by Language Editor |
|
2014-03-25 11:28 |
|
Typeset the Manuscript |
|
2014-04-11 09:52 |
|
Publish the Manuscript Online |
|
2014-04-18 11:34 |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Field of Vision |
| Article Title |
Antidiabetic treatment, stroke severity and outcome
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Dimitra Magkou and Konstantinos Tziomalos |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Konstantinos Tziomalos, MD, PhD, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 St. Kyriakidi, Thessaloniki 54636, Greece. ktziomalos@yahoo.com |
| Key Words |
Type 2 diabetes mellitus; Stroke; Dipeptidyl peptidase-4 inhibitors; Sulfonylureas; Neuroprotection |
| Core Tip |
A recent study showed reduced stroke size following pretreatment with linagliptin, a dipeptidyl peptidase-4 (DDP-4) inhibitor, compared with glimepiride, in both diabetic and non-diabetic mice. It remains to be shown whether these neuroprotective actions of DPP-4 inhibitors will also be observed in humans. |
| Publish Date |
2014-04-18 11:34 |
| Citation |
Magkou D, Tziomalos K. Antidiabetic treatment, stroke severity and outcome. World J Diabetes 2014; 5(2): 84-88 |
| URL |
http://www.wjgnet.com/1948-9358/full/v5/i2/84.htm |
| DOI |
http://dx.doi.org/10.4239/wjd.v5.i2.84 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
